Dr Markus Wang > Bär & Karrer Ltd. > Zurich, Switzerland > Lawyer Profile

Capitalising on its significant experience in the Federal Patent Court and the Federal Supreme Court, Bär & Karrer Ltd. is able to represent Novartis, Sandoz and a variety of other clients in high-stakes mandates. Operating across technology, life sciences and consumer goods industries among others, the experienced team is routinely entrusted with significant transactional work as well as specialised IP transactions. The practice is led by Markus Wang, who is especially noted for his extensive capabilities across a range of contentious and non-contentious work, and he is particularly active in the pharma, biotech and IT sector.

Bär & Karrer Ltd.’s team advises and represents telecommunication companies, cable network providers, social media companies, and broadcasting companies on the full spectrum of TMT matters from outsourcing projects, complex software contracts, regulatory advice to media rights-related arbitration procedures or joint ventures in the IT industry. The team is co-headed by Michele Bernasconi and Christian Kunz, with Bernasconi having expertise in international litigation and arbitration as well as in commercial and transactional work relating to TMT activities, and Kunz having advised on data-driven business models and platform solutions as well as advanced technology projects, AI, digital infrastructure, and technology transactions. Markus Wang, who handles both contentious and non-contentious work in the pharmaceutical, biotech and IT sectors, and Corrado Rampini, who is an expert in Swiss and international data protection and privacy law, both support the team.

The market-leading team at Bär & Karrer Ltd. advises its lucrative client base of on the full gamut of matters, including the marketing and advertising of drugs and pricing proceedings. Jointly heading the practice in Zurich, Markus Schott primarily focuses on administrative proceedings, including government supervision and public procurement mandates; Markus Wang  leads on the intellectual property (IP) side, acting for pharma and biotech clients in Swissmedic proceedings; and Philippe Seiler maintains a private equity and M&A focused practice, handling a variety of transactions and regulatory matters involving medical device and drug distribution. Basel based practice co-head Claudia Götz Staehelin is an expert in investigations, disputes, and regulatory issues, representing numerous global pharma giants, while co-head Oliver Brupbacher is noted for his ‘exceptional‘ sector knowledge, and his expertise in crisis management issues and information governance. Jannick Koller left the practice in December 2022.